Dosage Forms

Apr 09, 2018
By Pharmaceutical Technology Editors
Roche has acquired a program to develop regenerative therapies for multiple sclerosis.
Apr 06, 2018
By Pharmaceutical Technology Editors
Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.
Apr 06, 2018
By Pharmaceutical Technology Editors
Anthony Qu, PhD, vice president of Scientific Affairs at Halo Pharma, will give a presentation on fixed-dose combination products, drug products containing multiple active ingredients, as an effective approach for simplified dosing at CPhI North America on Wednesday, April 25, 2018 in Philadelphia, PA.
Apr 05, 2018
Pharmaceutical Technology's In the Lab eNewsletter
By Pharmaceutical Technology Editors
The active pharmaceutical ingredient and excipient provider has expanded its parenteral ingredient manufacturing capacity and lab services.
Apr 05, 2018
By Pharmaceutical Technology Editors
Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.
Apr 05, 2018
By Pharmaceutical Technology Editors
The European approval marks the first approval for a biosimilar in that region resulting from the companies’ joint portfolio.
Apr 05, 2018
By Pharmaceutical Technology Editors
The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.
Apr 05, 2018
By Pharmaceutical Technology Editors
Colorcon Inc. and Applied DNA signed a supply agreement granting Colorcon exclusive right to use Applied DNA’s SigNature molecular tags in film coatings for solid oral dosage forms, and non-exclusive rights to use it in inks and colorants for SOD pharmaceuticals.
Apr 03, 2018
By Pharmaceutical Technology Editors
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
Apr 03, 2018
By Pharmaceutical Technology Editors
The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.
native1_300x100
lorem ipsum